Overview

Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The objective of this survey was to understand the safety and efficacy of PAXIL tablets ("PAXIL", hereinafter) when it was started at 20 mg/day in subjects with depression or in a depressed state.
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Paroxetine